Metformin use was associated with a 24% lower risk of all-cause mortality during the first six months of treatment in men with diabetes and prostate cancer compared with nonusers, a study indicated. Researchers also found that each additional six-month period of metformin treatment was tied to 44% lower odds of prostate cancer-specific mortality and a 20% decreased risk of all-cause mortality. The results appear in the Journal of Clinical Oncology.
Metformin boosts survival in men with diabetes, prostate cancer
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.